Literature DB >> 17721036

Robotically assisted multivessel minimally invasive direct coronary artery bypass grafting with the use of bilateral internal thoracic arteries.

Satoru Nishida1, Tamotsu Yasuda, Go Watanabe, Yujiro Kikuchi, Yoshiko Shintani, Shigeki Ito, Shigeki Tabata, Kenji Kawachi.   

Abstract

This case report presents the robotically assisted multivessel minimally invasive direct coronary artery bypass grafting (MIDCAB) technique using the bilateral internal thoracic arteries. A 54-year-old man with multivessel coronary artery disease was considered eligible for a robotically assisted myocardial revascularization. The bilateral internal thoracic arteries were harvested completely in a totally skeletonized fashion through three 1-2-cm-long incisions on the left thoracic wall. A small left anterior thoracotomy was then performed. The left internal thoracic artery was anastomosed to the left anterior descending coronary artery, and the composite radial artery graft from the right internal thoracic artery was sequentially anastomosed to the first diagonal branch, the obtuse marginal branch, and the distal right coronary artery on the beating heart without cardiopulmonary bypass. The harvesting time of the grafts was 66 min, and the total operative time was 5 h 58 min. Postoperative angiography revealed that all grafts were widely patent. The postoperative course was uneventful, and the patient was discharged 10 days after the operation. Robotically assisted MIDCAB using the bilateral thoracic arteries is a safe and effective means of myocardial revascularization for patients with multivesssel disease.

Entities:  

Mesh:

Year:  2007        PMID: 17721036     DOI: 10.1253/circj.71.1496

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  1 in total

1.  Beating-heart totally endoscopic coronary artery bypass grafting: report of a case.

Authors:  Satoru Nishida; Go Watanabe; Norihiko Ishikawa; Yujiro Kikuchi; Munehisa Takata; Teruaki Ushijima
Journal:  Surg Today       Date:  2009-12-29       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.